Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected
By Antti Luiro
Translation: Original published in Finnish on 02/07/2025 at 8:00 am EET
The funds raised in the issue will strengthen the company's financial position until the topline data of the HER-096 phase 1b trial are released in Q3'25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial. The share issue will be carried out at a price of EUR 1.32 per share, which represents a discount of -12% to yesterday's closing price of EUR 1.5 per share and raises the company's number of shares by some 20%. The funding is almost exactly in line with our expectations in size (Assumption: 5 MEUR), timing (Assumption: early 2025) and valuation (Assumption: EUR 1.36 per share) and therefore contains no surprises. Thus, the release only necessitates minor revisions to our forecasts. We will update our forecasts and views on the company in connection with the financial statements release to be published on March 6.
Login required
This content is only available for logged in users
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read more on company pageKey Estimate Figures23.08.2024
| 2023 | 24e | 25e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | 150.0 % | ||
| EBIT (adj.) | 0.2 | -5.3 | -5.0 |
| EBIT-% (adj.) | 3,850.0 % | -52,560.0 % | -49,520.0 % |
| EPS (adj.) | 0.01 | -0.26 | -0.21 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | 114.2 | neg. | neg. |
| EV/EBITDA | 165.2 | neg. | neg. |
Forum discussions
